Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/n-SVmIdnUak   Type 2 diabetics using GLP-1 receptor agonists that lower blood glucose and hemoglobin A1C are more likely to experience mild CoVid infections that don’t put them in the ICU, on ventilators, or on an autopsy slab.  Researchers at Penn State reviewed the electronic medical records of nearly 30,000 type 2 diabetics testing positive for CoVid during the pre-vaccine 2020’s.  Of these about 7,000 were on these drugs and 23,000 were not.   Those CoVid patients taking these GLP-1 receptor agonists like semaglutide, more familiar to TV viewers as Trulicity and Victoza, within 6 months of their CoVid diagnosis showed a 33% lower risk of hospitalization, a 38.4% lower risk of major respiratory complications, and a 42.1% lower risk of death.   Studies are continuing to clarify if this protective phenomenon is directly due this class of drugs.  The investigators also want to know if GLP-1- receptor agonists can also protect non-diabetics.   https://diabetes.diabetesjournals.org